Press Releases

;

105 Patient groups detail to FTC PBM practices that harm access and affordability of Drugs

May 24, 2022

Today, the HIV+Hepatitis Policy Institute (HIV+Hep) and the Autoimmune Association, along with 103 other organizations representing a broad range of patients across the country, submitted comments to the Federal Trade Commission (FTC) in response to a Request for Information (RFI) on the impact of pharmacy benefit manager (PBM) practices and the ability of patients to access and afford their prescription medications.

read more

Biden administration takes big step in making drugs affordable for patients: Also strengthens nondiscrimination protections

Apr 28, 2022

In reaction to the Biden administration’s announcement today that insurers on the federal exchange must offer standard plans, which for the most part use reasonable copay limits for prescription drugs, Carl Schmid, executive director, HIV+Hepatitis Policy Institute (HIV+Hep), issued the following statement: “This is a huge win for patients. Insurers have made it almost impossible for patients to afford their medications by first requiring them to meet a high deductible and then charging high co-insurance, which is a percentage of the list price of the drug. By limiting patient copays and keeping more drugs outside of the deductible, patients will be better able to afford their medications. We only wish the Biden administration would have applied these principles to more metal levels and drug tiers, but this provides better options for people who rely on prescription drugs.”

read more

Biden Budget Boosts Domestic HIV Funding & Proposes Nationwide PrEP Delivery Program: CDC Hepatitis Program Receives Increase

Mar 28, 2022

President Biden is proposing an increase of $377 million for the Ending the HIV Epidemic in the U.S. initiative for a total of $850 million for efforts to end HIV by 2030. Additionally, in response to the HIV community and several members of Congress’ request to develop a program to increase access to PrEP, which are medications that prevent HIV, the president’s budget calls for the creation of an ambitious ten-year $9.8 billion nationwide PrEP delivery program. The budget includes numerous other program increases, including a bump of $13.5 million for the CDC’s hepatitis division.

read more

Congressional funding slows for ending HIV initiative: Hepatitis programs left with a minimal increase

Mar 9, 2022

In the omnibus appropriations bill released today, Congress has significantly slowed the increase of funding for the Ending the HIV Epidemic in the U.S. initiative and put in jeopardy efforts to end HIV by 2030. Instead of supporting an increase of $245 million, as was proposed in President Biden’s budget and passed by the House and proposed by Senate Democratic leaders, the final bill allocates an increase of only $70 million for HIV testing, prevention, treatment, and research programs for those jurisdictions most impacted by HIV.

read more

Job Announcement: Health Policy Manager

Feb 10, 2022

The HIV+Hepatitis Policy Institute is seeking a Health Policy Manager to help fulfill our policy goals to increase access and affordability of PrEP for the prevention of HIV and ensure patient access to healthcare and treatment for those with private insurance, Medicaid, and Medicare.

read more

Search

Press Release Tags

ACA Appropriations Biden administration CDC Congress Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing Gay men healthcare Hepatitis Hepatitis C hepatits HIV HIV Prevention hous housing Insurers Medicaid Medicare Part D NIH PBMs PrEP Prescription Drugs prevention Private Insurance Ryan White Ryan White Program Syringe services Testing transparency Treatment Trump administration

Recent Press Releases

Pin It on Pinterest